Anti-Angiogenic Properties of Postbiotics Derived from Lactic Acid Bacteria Against Colorectal Cancer In Vitro.

Introduction: The emergence of side effects and cancer resistance, which compromises the efficacy of current chemotherapy and targeted therapy against colorectal cancer (CRC), raises the need for alternative approaches to prevent and/or manage CRC. Given that CRC is angiogenesis-dependent, the present study examined the anti-angiogenic potential of postbiotics derived from four unique strains of lactic acid bacteria (LAB; i.e., Lactiplantibacillus plantarum LAB1, Pediococcus pentosaceus LAB3, P. acidilactici LAB4 and L. plantarum LAB12) isolated from fermented food in vitro. Methods: The postbiotics derived from LAB were assessed for their anti-angiogenicity against human umbilical vein endothelial cells (HUVEC) using both scratch and tube formation assays. The effects of LAB-derived postbiotics against regulation of the expressions of RhoA, vascular endothelial growth factor (VEGF) and thrombospondin (TSP-1) in the HCT116 colorectal cancer cell line were then examined using immunocytochemistry. Results: Out of the four LAB postbiotics, LAB12-derived postbiotics possessed the best anti-angiogenic properties against migration and differentiation of HUVEC. Immunocytostaining of HCT116 cells treated with LAB12-derived postbiotics showed reduced formation of stress fibers, indicating inactivation of active RhoA. The immunocytochemistry findings also showed downregulation of VEGF but upregulation of TSP-1, indicating inhibition of the angiogenic switch in HCT116 cells. Conclusion: The present findings strongly implied the anti-angiogenic potential of LAB12-derived postbiotics and warrants further validation using in vivo models. [ABSTRACT FROM AUTHOR]